Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:2662
Structure:
Synonyms:
169590-42-5
184007-95-2
194044-54-7
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonami
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AI-525
Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-
Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celecox
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [USAN]
Celocoxib
CHEBI:41423
cMAP_000027
D00567
DB00482
DivK1c_000893
Heumann brand of celecoxib
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
KS-1041
LS-31667
Mack brand of celecoxib
MLS001165684
MLS001195656
MLS001304708
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Parke Davis brand of celecoxib
Pfizer brand of celecoxib
Pharmacia brand of celecoxib
Pharmacia Spain brand of celecoxib
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
Searle brand of celecoxib
SMR000550473
Solexa
SPBio_001512
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
STOCK6S-51468
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
ATC-Codes:
Side-Effects:
Side-EffectFrequency
headache0.1465
hypertension0.125
dyspepsia0.0776
upper respiratory tract infection0.0754
diarrhea0.058166668
sinusitis0.0472
gastroesophageal reflux disease0.047
nausea0.036857147
abdominal pain0.035800003
back pain0.031200001
dyspnea0.028
insomnia0.023
rash0.021599999
pharyngitis0.0182
rhinitis0.017199999
flatulence0.017199999
peripheral edema0.016999999
vomiting0.0165
dizziness0.015833333
vasculitis0.0010
fever0.0010
pulmonary embolism0.0010
vascular disorders0.0010
gangrene0.0010
osteitis0.0010
myositis0.0010
interstitial nephritis0.0010
pancytopenia0.0010
ventricular fibrillation0.0010
ulceration0.0010
esophageal perforation0.0010
pain0.0010
pancreatitis0.0010
erythema multiforme0.0010
epilepsy0.0010
toxic epidermal necrolysis0.0010
gastrointestinal bleeding0.0010
myocardial infarction0.0010
cardiac disorders0.0010
hypoglycemia0.0010
thrombocytopenia0.0010
hyponatremia0.0010
intestinal perforation0.0010
jaundice0.0010
syncope0.0010
stevens johnson syndrome0.0010
acute renal failure0.0010
leukopenia0.0010
thrombophlebitis0.0010
heart failure0.0010
congestive heart failure0.0010
bleeding0.0010
hepatitis0.0010
menstrual disorder0.0010
skin erythema0.0010
mediastinal disorders0.0010
allergic reactions0.0010
cerebrovascular accident0.0010
bronchospasm0.0010
angioedema0.0010
anosmia0.0010
confusion0.0010
acute pancreatitis0.0010
connective tissue disorders0.0010
aseptic meningitis0.0010
colitis0.0010
cholelithiasis0.0010
arthritis0.0010
breast disorders0.0010
transient ischemic attacks0.0010
ataxia0.0010
sepsis0.0010
deep venous thrombosis0.0010
angina0.0010
aplastic anemia0.0010
hallucinations0.0010
exfoliative dermatitis0.0010
anaphylactic shock0.0010
agranulocytosis0.0010
dysmenorrhea0.0010
liver failure0.0010
intracranial hemorrhage0.0010
decreased hearing0.0010
increased sweating0
tinnitus0
neuropathy0
synovitis0
blurred vision0
photosensitivity0
pruritus0
hypophosphatemia0
thrombocythemia0
proteinuria0
pneumonia0
paresthesia0
urinary frequency0
skin nodule0
elevated blood pressure0
breast neoplasm0
stomatitis0
tachycardia0
vaginal hemorrhage0
weight gain0
uveitis0
neck rigidity0
vaginitis0
migraine0
bronchitis0
cataract0
sinus bradycardia0
vertigo0
viral infection0
liver function tests abnormal0
urticaria0
hyperchloremia0
tendinitis0
tenesmus0
abdominal pain upper0
tooth disorder0
myalgia0
dry skin0
urinary incontinence0
urinary tract infection0
sgot increased0
alkaline phosphatase increased0
eye pain0
dry mouth0
adenomas0
coronary artery disease0
cough0
cystitis0
cyst0
deafness0
dysphagia0
dermatitis0
contact dermatitis0
diabetes mellitus0
diverticulitis0
somnolence0
dysuria0
ear pain0
ecchymosis0
edema0
constipation0
conjunctivitis0
albuminuria0
alopecia0
anemia0
anorexia0
anxiety0
aortic valve incompetence0
arthralgia0
asthenia0
bacterial infections0
clotting0
moniliasis0
cellulitis0
cerebral infarction0
cerebrovascular disorder0
chest pain0
epicondylitis0
epistaxis0
eructation0
arthrosis0
kidney calculus0
labyrinthitis0
laryngitis0
leg cramps0
breast pain0
melena0
fungal infection0
nail disorder0
nasopharyngitis0
nervousness0
neuralgia0
gastroenteritis0
otitis media0
ovarian cyst0
influenza0
infection0
esophagitis0
fatigue0
vitreous floaters0
flushing0
gastritis0
glaucoma0
hematuria0
hemorrhoids0
hiatal hernia0
herpes simplex0
herpes zoster0
hypercholesterolemia0
hyperglycemia0
hypersensitivity0
hypokalemia0
palpitations0

Target

show target details
Uniprot ID:CAH2_HUMAN
Synonyms:
CA-II
CAC
Carbonate dehydratase II
Carbonic anhydrase 2
Carbonic anhydrase C
Carbonic anhydrase II
EC-Numbers:4.2.1.1
Organism:Homo sapiens
Human
PDB IDs:12CA 1A42 1AM6 1AVN 1BCD 1BIC 1BN1 1BN3 1BN4 1BNM 1BNN 1BNQ 1BNT 1BNU 1BNV 1BNW 1BV3 1CA2 1CA3 1CAH 1CAI 1CAJ 1CAK 1CAL 1CAM 1CAN 1CAO 1CAY 1CAZ 1CCS 1CCT 1CCU 1CIL 1CIM 1CIN 1CNB 1CNC 1CNG 1CNH 1CNI 1CNJ 1CNK 1CNW 1CNX 1CNY 1CRA 1CVA 1CVB 1CVC 1CVD 1CVE 1CVF 1CVH 1DCA 1DCB 1EOU 1F2W 1FQL 1FQM 1FQN 1FQR 1FR4 1FR7 1FSN 1FSQ 1FSR 1G0E 1G0F 1G1D 1G3Z 1G45 1G46 1G48 1G4J 1G4O 1G52 1G53 1G54 1H4N 1H9N 1H9Q 1HCA 1HEA 1HEB 1HEC 1HED 1HVA 1I8Z 1I90 1I91 1I9L 1I9M 1I9N 1I9O 1I9P 1I9Q 1IF4 1IF5 1IF6 1IF7 1IF8 1IF9 1KWQ 1KWR 1LG5 1LG6 1LGD 1LUG 1LZV 1MOO 1MUA 1OKL 1OKM 1OKN 1OQ5 1RAY 1RAZ 1RZA 1RZB 1RZC 1RZD 1RZE 1T9N 1TB0 1TBT 1TE3 1TEQ 1TEU 1TG3 1TG9 1TH9 1THK 1TTM 1UGA 1UGB 1UGC 1UGD 1UGE 1UGF 1UGG 1XEG 1XEV 1XPZ 1XQ0 1YDA 1YDB 1YDC 1YDD 1YO0 1YO1 1YO2 1Z9Y 1ZE8 1ZFK 1ZFQ 1ZGE 1ZGF 1ZH9 1ZSA 1ZSB 1ZSC 2ABE 2AW1 2AX2 2CA2 2CBA 2CBB 2CBC 2CBD 2CBE 2EU2 2EU3 2EZ7 2F14 2FMG 2FMZ 2FNK 2FNM 2FNN 2FOQ 2FOS 2FOU 2FOV 2GD8 2GEH 2H15 2H4N 2HD6 2HKK 2HL4 2HNC 2HOC 2ILI 2NNG 2NNO 2NNS 2NNV 2NWO 2NWP 2NWY 2NWZ 2NXR 2NXS 2NXT 2O4Z 2OSF 2OSM 2POU 2POV 2POW 2Q1B 2Q1Q 2Q38 2QO8 2QOA 2QP6 2VVA 2VVB 3B4F 3BET 3BL0 3BL1 3C7P 3CA2 3CAJ 3CYU 3D8W 3D92 3D93 3D9Z 3DAZ 3DBU 3DC3 3DC9 3DCC 3DCS 3DCW 3DD0 3DD8 3DV7 3DVB 3DVC 3DVD 3EFT 3F4X 3FFP 3GZ0 3IBI 3IBL 3IBN 3IBU 4CA2 4CAC 5CA2 5CAC 6CA2 7CA2 8CA2 9CA2
Structure:
9CA2

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----
----
----
--21-
--21-
21---
21---
21000---

References:

16290146
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.. Anna Di Fiore; Carlo Pedone; Katia D'Ambrosio; Andrea Scozzafava; Giuseppina De Simone; Claudiu T Supuran (2006) Bioorganic & medicinal chemistry letters display abstract
The high resolution X-ray crystal structure of the adduct of human carbonic anhydrase (CA, EC 4.2.1.1) isoform II (hCA II) with the clinically used painkiller valdecoxib, acting as a potent CA II and cyclooxygenase-2 (COX-2) inhibitor, is reported. The ionized sulfonamide moiety of valdecoxib is coordinated to the catalytic Zn(II) ion with a tetrahedral geometry. The phenyl-isoxazole moiety of the inhibitor fills the active site channel and interacts with the side chains of Gln92, Val121, Leu198, Thr200, and Pro202. Its 3-phenyl group is located into a hydrophobic pocket, simultaneously establishing van der Waals interactions with the aliphatic side chain of various hydrophobic residues (Val135, Ile91, Val121, Leu198, and Leu141) and a strong offset face-to-face stacking interaction with the aromatic ring of Phe131 (the chi1 angle of which is rotated about 90 degrees with respect to what was observed in the structure of the native enzyme and those of other sulfonamide complexes). Celecoxib, a structurally related COX-2 inhibitor for which the X-ray crystal structure was reported earlier, binds in a completely different manner to hCA II as compared to valdecoxib. Celecoxib completely fills the entire CA II active site, with its trifluoromethyl group in the hydrophobic part of the active site and the p-tolyl moiety in the hydrophilic one, not establishing any interaction with Phe131. In contrast to celecoxib, valdecoxib was rotated about 90 degrees around the chemical bond connecting the benzensulfonamide and the substituted isoxazole ring allowing for these multiple favorable interactions. These different binding modes allow for the further drug design of various CA inhibitors belonging to the benzenesulfonamide class.
SuperTarget